Abstract and Introduction
Introduction
On March 18, 2019, the Food and Drug Administration (FDA) extended the approval for dupilumab to include adolescents 12 to 17 years of age for the treatment of moderate to severe atopic dermatitis not adequately controlled by topical treatment.[1] It may be used alone or in conjunction with topical corticosteroids or topical calcineurin inhibitors applied in limited problem areas. Dupilumab was initially approved by the FDA on March 28, 2017 for use in adults with atopic dermatitis. On October 19, 2018, it was approved for adults and adolescents with moderate-to-severe asthma who have an eosinophilic phenotype or have oral corticosteroid-dependent asthma. This newest action by the FDA makes dupilumab the first biologic to be approved for atopic dermatitis in younger patients.[1–3]
Pediatr Pharm. 2019;25(6) © 2019 University of Virginia
